<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03362879</url>
  </required_header>
  <id_info>
    <org_study_id>P16-831</org_study_id>
    <nct_id>NCT03362879</nct_id>
  </id_info>
  <brief_title>COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel</brief_title>
  <acronym>COSMOS</acronym>
  <official_title>COSMOS - COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate treatment of advanced Parkinson's Disease (PD)
      patients on levodopa-carbidopa intestinal gel (LCIG) monotherapy in a routine clinical
      setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with advanced Parkinson's Disease who have been prescribed LCIG for at least 12
      months will be entered into the study cohort. Clinical data will be collected by
      retrospective review of the patient's medical records as well as a single study visit for
      current data. Treatment of the patients and follow up will be according to the physician's
      judgment, regional regulations and the product monograph.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2017</start_date>
  <completion_date type="Anticipated">December 14, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 14, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients on Levodopa-Carbidopa Intestinal Gel (LCIG) monotherapy from LCIG initiation to 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>The percentage of patients on LCIG monotherapy from immediately following LCIG initiation to 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients on LCIG monotherapy from immediately following LCIG initiation to 12 months in participating countries with at least 20 subjects enrolled</measure>
    <time_frame>12 months</time_frame>
    <description>The percentage of patients on LCIG monotherapy from immediately following LCIG initiation to 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from initial LCIG administration to the initiation of LCIG monotherapy</measure>
    <time_frame>12 months</time_frame>
    <description>The time from the initiation of LGIC therapy to the initiation of LCIG as monotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from initial LCIG administration to the introduction or tapering of each PD medication or substantial dose adjustments.</measure>
    <time_frame>12 months</time_frame>
    <description>The time from the initial LCIG administration to the introduction or tapering of each PD medication or substantial dose adjustments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Preference for pharmacological treatment approach</measure>
    <time_frame>12 months</time_frame>
    <description>The overall preference for treatment using LCIG as monotherapy compared with LCIG plus add-on PD medication, as stated by of the physician and the patient/caregiver.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LCIG infusion settings</measure>
    <time_frame>12 months</time_frame>
    <description>Final LCIG settings upon completion of initial titration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substantial LCIG dose adjustments</measure>
    <time_frame>12 months</time_frame>
    <description>The percentage of patients with substantial LCIG dose adjustments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from initial LCIG administration to the introduction or tapering of each PD medication or substantial dose adjustments in participating countries with at least 20 subjects enrolled.</measure>
    <time_frame>12 months</time_frame>
    <description>The time from initial LCIG administration to the introduction or tapering of each PD medication or substantial dose adjustments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCRU in participating countries with at least 20 subjects enrolled.</measure>
    <time_frame>12 months</time_frame>
    <description>The HCRU questionnaire is used to assess healthcare resource utilization, including occupational status, nursing home visits, hospitalizations/emergency care visits and reason, caregiver support, and patient´s opinion on Parkinson's Disease medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Disease (PD) medication management</measure>
    <time_frame>12 months</time_frame>
    <description>Medication management for PD from immediately prior to LCIG initiation to 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare resource utilization questionnaire (HCRU)</measure>
    <time_frame>12 months</time_frame>
    <description>The HCRU questionnaire is used to assess healthcare resource utilization, including occupational status, nursing home visits, hospitalizations/emergency care visits and reason, caregiver support, and patient´s opinion on PD medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors for achieving long-term therapy</measure>
    <time_frame>12 months</time_frame>
    <description>Patient and physician profiles will be used to identify predictors for achieving long-term monotherapy with LCIG compared with LCIG plus add-on PD medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of LCIG monotherapy</measure>
    <time_frame>12 months</time_frame>
    <description>The mean duration of LCIG monotherapy.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Parkinson's Disease (PD)</condition>
  <arm_group>
    <arm_group_label>Patients with Advanced Parkinson's Disease</arm_group_label>
    <description>Patients with advanced Parkinson's Disease on current treatment with levodopa-carbidopa intestinal gel (LCIG) for at least 12 months.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with Advanced Parkinson's Disease (APD), on current treatment with
        levodopa-carbidopa intestinal gel (LCIG), and treated with LCIG for at least 12 months
        prior to enrollment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with APD and on LCIG treatment for at least 12 months

          -  Patient must have been on continuous LCIG treatment for at least 80% of days in the
             preceding year

          -  Patients must be treated by the same physician (PI or co-investigator) since the
             initiation of LCIG treatment

        Exclusion Criteria:

          -  Participation in a concurrent or a previous interventional clinical trial during which
             the patient was on LCIG therapy

          -  Lack of motivation or insufficient language skills to complete the study
             questionnaires
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anita Johnson</last_name>
    <phone>847-936-5375</phone>
    <email>anita.johnson@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rebecca Padula</last_name>
    <email>rebecca.padula@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gailtal Klinik</name>
      <address>
        <city>Hermagor-Pressegger See</city>
        <state>Karnten</state>
        <zip>9620</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CRCHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aiginiteio University Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Heraklion</name>
      <address>
        <city>Heraklion</city>
        <state>Kriti</state>
        <zip>711 10</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>HYGEIA Hospital</name>
      <address>
        <city>Athens</city>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mediterraneo Hospital</name>
      <address>
        <city>Glyfada</city>
        <zip>16675</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Ioannin</name>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem</name>
      <address>
        <city>Pécs</city>
        <state>Pecs</state>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Borsod-Abauj-Zemplen Megyei</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bons Secours Hospital</name>
      <address>
        <city>Cork</city>
        <zip>00000</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <zip>T12 E8YV</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <zip>H91 YR71</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Ctr</name>
      <address>
        <city>Tel Aviv-Yafo</city>
        <state>Tel-Aviv</state>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinic Fundeni Institute</name>
      <address>
        <city>Bucharest</city>
        <state>Bucuresti</state>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colentina Clinical Hospital</name>
      <address>
        <city>Bucharest</city>
        <zip>20125</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ Emergency Hosp Bucharest</name>
      <address>
        <city>Bucuresti</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rehabilitation Clinical Hosp</name>
      <address>
        <city>Iasi</city>
        <zip>700661</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oradea County Clinical</name>
      <address>
        <city>Oradea</city>
        <zip>410167</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emergency Clinical County Hosp</name>
      <address>
        <city>Targu Mures</city>
        <zip>540042</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Timisoara County</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Timisoara County</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AbbVie Farmaceutica SLU</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum for neurologi</name>
      <address>
        <city>Stockholm</city>
        <zip>113 65</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurologmottagningen</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2017</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Parkinson's Disease</keyword>
  <keyword>Levodopa-Carbidopa Intestinal Gel (LCIG)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

